These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1888828)

  • 41. Mucosal metabolism in ulcerative colitis and Crohn's disease.
    Duffy MM; Regan MC; Ravichandran P; O'Keane C; Harrington MG; Fitzpatrick JM; O'Connell PR
    Dis Colon Rectum; 1998 Nov; 41(11):1399-405. PubMed ID: 9823806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease].
    Bayerdörffer E; Bock H
    Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
    Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sulfasalazine and 5-ASA compounds.
    Allgayer H
    Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Gut; 1973 Aug; 14(8):631-41. PubMed ID: 4147555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
    Laerum OD; Illemann M; Skarstein A; Helgeland L; Ovrebø K; Danø K; Nielsen BS
    Am J Gastroenterol; 2008 Sep; 103(9):2350-8. PubMed ID: 18844621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis.
    Pooley N; Ghosh L; Sharon P
    Dig Dis Sci; 1995 Jan; 40(1):219-25. PubMed ID: 7529672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum nitrate levels in ulcerative colitis and Crohn's disease.
    Oudkerk Pool M; Bouma G; Visser JJ; Kolkman JJ; Tran DD; Meuwissen SG; Peña AS
    Scand J Gastroenterol; 1995 Aug; 30(8):784-8. PubMed ID: 7481547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Mesalazine old and new].
    Mañosa M; Domènech E
    Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():25-9. PubMed ID: 25443223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.
    Adar T; Shteingart S; Ben-Ya'acov A; Shitrit AB; Livovsky DM; Shmorak S; Mahamid M; Melamud B; Vernea F; Goldin E
    Dig Dis Sci; 2016 Jul; 61(7):1915-24. PubMed ID: 26874691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
    Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G
    J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid.
    Peskar BM; Dreyling KW; Peskar BA; May B; Goebell H
    Agents Actions; 1986 Jun; 18(3-4):381-3. PubMed ID: 2875632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug treatment of chronic inflammatory intestinal diseases with special reference to 5-azosalicylic acid].
    Fahrländer H
    Schweiz Med Wochenschr; 1987 Oct; 117(42):1620-3. PubMed ID: 3321418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytokine production in patients with inflammatory bowel disease.
    Nakamura M; Saito H; Kasanuki J; Tamura Y; Yoshida S
    Gut; 1992 Jul; 33(7):933-7. PubMed ID: 1644332
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
    Szewczuk MR; Depew WT
    Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.